Atomoxetine treatment strengthens an anti-correlated relationship between functional brain networks in medication-naïve adults with attention-deficit hyperactivity disorder: a randomized double-blind placebo-controlled clinical trial.
Int J Neuropsychopharmacol. 2015 Sep 16;
Authors: Lin HY, Gau SS
Abstract
BACKGROUND: Although atomoxetine demonstrates efficacy in individuals with attention-deficit hyperactivity disorder (ADHD), its treatment effects on brain resting-state functional connectivity (RSFC) remain unknown. Therefore, we aimed to investigate (1) major brain functional networks in medication-naïve adults with ADHD and (2) the efficacy of atomoxetine treatment on RSFC.
METHODS: After collecting baseline resting-state functional MRI scans from 24 adults with ADHD (aged 18 to 52 years) and 24 healthy controls (matched in demographic characteristics), the participants with ADHD were randomly assigned to atomoxetine (n = 12) and placebo (n = 12) arms in an 8-week double-blind, placebo-controlled trial. The primary outcome was functional connectivity assessed by a resting-state functional MRI. Seed-based functional connectivity was calculated and compared for the affective, attention, default, and cognitive control networks.
RESULTS: At baseline, we found atypical cross talk between the default, cognitive control, and dorsal attention networks, and hypoconnectivity within the dorsal attention and default networks in adults with ADHD. Our first-ever placebo-controlled clinical trial incorporating resting-state functional MRI showed that treatment with atomoxetine strengthened an anti-correlated relationship between the default and task-positive networks, and modulated all major brain networks. The strengthened anticorrelations were associated with improving clinical symptoms in the atomoxetine-treated adults.
CONCLUSIONS: Our results support the idea that atypical DMN-task positive networks interaction plays an important role in the pathophysiology of adult ADHD. Strengthening this atypical relationship following atomoxetine treatment suggests an important pathway to treat ADHD.
PMID: 26377368 [PubMed – as supplied by publisher]
